Report Highlights

U.S. Non-Invasive Monitoring Devices: Market Overview

The U.S. non-invasive monitoring device market is the world's largest single-country segment, accounting for roughly 38% of global revenue in 2024 and valued at USD 6.8 billion. Unlike the global norm, where emerging markets drive unit volumes through low-cost pulse oximeters, the U.S. market is value-led, with demand concentrated in multiparameter bedside systems, capnography, and cuff-based hemodynamic monitoring. Hospitals and ambulatory surgical centers absorb most capital spend, while home-use devices grow fastest.

Pricing is set less by the device than by the reimbursement code behind it. Pulse oximetry sits within hospital capital budgets and Medicare Part B durable medical equipment coverage, whereas remote physiological monitoring is paid through CPT 99457 and 99458 under the Medicare Physician Fee Schedule. That split means a single sensor can sit in two revenue streams, and vendors that bundle disposable sensors with software subscriptions capture the recurring margin that hardware-only competitors cannot.

Growth Drivers in U.S. Non-Invasive Monitoring

Medicare reimbursement for remote physiological monitoring is the strongest demand driver. CMS expanded the Physician Fee Schedule in 2025 with CPT 99445 and 99470 alongside established codes 99457 and 99458, allowing practices to bill for shorter monitoring episodes. With over 90 percent of Medicare beneficiaries living with at least one chronic condition, practices deploy wireless blood pressure cuffs and pulse oximeters to meet billing thresholds. Vendors that integrate devices with EHR platforms such as Epic gain placement in these programs first.

Hospital capacity pressure forms the second driver. U.S. hospitals have operated at elevated occupancy since 2022, pushing general wards toward continuous non-invasive monitoring to catch deterioration early. The Acute Hospital Care at Home waiver, repeatedly extended by Congress, requires remote vital-sign and pulse oximetry capture, while the Census Bureau projects 73 million Americans aged 65 or older by 2030, expanding the home-monitoring base. Hospitals facing readmission penalties under the Hospital Readmissions Reduction Program use these devices for discharge monitoring.

Market Restraints and Entry Barriers

FDA premarket pathways are the first barrier. Most non-invasive monitors enter through 510(k) clearance, but any sensor claiming new analytical capability, such as noninvasive hemoglobin or blood glucose, faces De Novo or PMA review. Starting in February 2026, the Quality Management System Regulation aligns FDA requirements with ISO 13485, forcing smaller entrants to rebuild documentation and audit trails before shipping a single unit. Section 524B cybersecurity requirements add a further submission layer for any connected device.

Incumbent contracting and reimbursement are the second barrier. Hospital group purchasing organizations such as Vizient and Premier negotiate multi-year agreements that bundle monitors with Philips IntelliVue and GE HealthCare Carescape systems, leaving little shelf space for new vendors. Pricing is further constrained by Medicare's DME fee schedule, meaning entrants must prove outcome value to win reimbursement rather than compete on unit price. Entrants without clinical evidence packages find those contracts closed.

Market Opportunities in the United States

Home-based hemodynamic monitoring offers the nearest-term opening. Acute hospital care at home and RPM billing both pay for cuff-based blood pressure and wearable pulse oximetry prescribed at discharge. Entrants with FDA-cleared home devices and EHR integration can address a Medicare base of roughly 68 million enrollees, with the home-use segment estimated at USD 3.0 billion by 2032. Vendors that secure a Medicare-approved billing code first will set reimbursement benchmarks for competitors.

Ambulatory surgical centers and emergency medical services present a second opening. Non-invasive cardiac output and capnography monitoring suit short-stay procedures where invasive arterial lines are avoided, and CMS continues adding procedures to the ambulatory surgery covered list, expanding the ASC base. Pre-hospital EMS agencies, which depend on Medicaid transport contracts, need rugged capnography and pulse oximetry units, and the Edwards ClearSight non-invasive platform illustrates demand for beat-to-beat blood pressure outside intensive care.

Market at a Glance

Leading Market Participants

• Masimo
• Medtronic
• Philips
• GE HealthCare
• Edwards Lifesciences
• Baxter International
• Nihon Kohden
• Omron Healthcare
• Nonin Medical
• Withings

Regulatory and Policy Environment

The FDA's Center for Devices and Radiological Health regulates these devices through 510(k), De Novo, and PMA pathways under the Federal Food, Drug, and Cosmetic Act. The Quality Management System Regulation, effective February 2, 2026, amends 21 CFR Part 820 with ISO 13485 alignment, and Section 524B requires cybersecurity plans, SBOMs, and patch commitments for connected monitors. Unique Device Identification rules under 21 CFR Part 830 require GUDID registration before commercial distribution.

CMS administers reimbursement through the Medicare Physician Fee Schedule and the DMEPOS benefit category, with the 2025 conversion factor set at USD 32.35 per relative value unit. Remote physiological monitoring billing under CPT 99457 requires a practitioner-established care plan and at least 20 minutes of clinical staff time in a calendar month. Vendors should also track HHS's ASTP/ONC certification and information-blocking rules, since interoperability with certified EHRs now determines hospital procurement eligibility.

Long-Term Outlook for U.S. Non-Invasive Monitoring

By 2032 the U.S. market is expected to reach USD 11.2 billion at a 6.4% CAGR, with hospital bedside systems growing slowly while home-use and wearable-linked devices expand at roughly twice that rate. Pulse oximetry and blood pressure cuffs become commoditized, pushing vendors such as Masimo, Nonin, and Omron toward subscription software and sensor-consumable models.

Regulatory and reimbursement shifts will decide the winners. Continued RPM code expansion, the 2026 QMSR transition, and cybersecurity enforcement under Section 524B favor vendors with mature quality systems and FDA-cleared software. Medtronic, Philips, and GE HealthCare will consolidate hospital installed bases, while mid-sized entrants win where they combine home devices with Medicare-billable care management.